Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
John Ostrominski
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Jonathan Cunningham, MD
Echo essentials for HCM: The heartbeat of diagnosis and treatment
Thor Edvardsen, MD, PhD
Maurizio Pieroni, MD, PhD
Elena Arbelo, MD, PhD
Role of echocardiography in risk stratification and treatment decision-making
Setting the Stage of Real-World Data vs RCT
Renato D. Lopes, MD, MHS, PhD
Implications Associated With Integrating Both Real-World Data and Clinical Trial Data Into Clinical Practice: AF Considerations
Valeria Caso, MD, PhD
Trade off: Ischemic/Thrombotic vs Bleeding
Pearls of Wisdom: Optimizing Hyperkalemia Management in Patients with CKD
Matthew R. Weir, MD
Nihar Desai, MD
Ellie Kelepouris, MD, FACP, FAHA
Optimizing AAV Outcomes: Maintenance Therapies
Bernhard Hellmich, MD
Silke R. Brix, MD, MRCP, SCPR
Patient Case Study: Elderly
Patient Case Study: Obesity and VTE
Alexander T. Cohen, MD, MBBS
Elevating Care for Patients With Severe Renal Disease in AAV
Andreas Kronbichler, MD
Tailoring Treatment for Optimal Outcomes in Patients With AAV
How Do We Translate Real-World VTE Data Into Everyday Clinical Practice for Ongoing Anticoagulation?
No Patient Left Behind! Advancing CKD-Associated Pruritus Care
Kieran McCafferty, MD
Maurizio Gallieni, MD
Breaking the Cycle: Addressing Hyperkalemia in CKD and Heart Failure to Optimize RAASi Therapy
Mikhail Kosiborod, MD
Stephen J. Greene, MD, FACC, FHFSA
Loading...
We're glad to see you're enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.